Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors
13 avr. 2023 17h00 HE
|
Oncternal Therapeutics
SAN DIEGO, April 13, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025
03 avr. 2023 16h01 HE
|
Oncternal Therapeutics
Zilovertamab Phase 3 Study ZILO-301 and Phase 1/2 Study CIRM-0001 to be closed based on dynamically changing therapeutic landscapeCash runway extended to 2025, enabling initial clinical data readouts...
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
27 mars 2023 09h00 HE
|
Oncternal Therapeutics
SAN DIEGO, March 27, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results
09 mars 2023 16h01 HE
|
Oncternal Therapeutics
Encouraging and improving interim Phase 1/2 study results for zilovertamab plus ibrutinib in patients with MCL and CLL, including those with mutated TP53 and/or del(17p), presented at ASH in December...
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results
02 mars 2023 17h00 HE
|
Oncternal Therapeutics
SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
01 mars 2023 17h00 HE
|
Oncternal Therapeutics
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
01 févr. 2023 17h00 HE
|
Oncternal Therapeutics
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors
04 janv. 2023 16h05 HE
|
Oncternal Therapeutics
SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
03 janv. 2023 17h00 HE
|
Oncternal Therapeutics
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022
10 déc. 2022 15h00 HE
|
Oncternal Therapeutics
Updated MCL and CLL data from the ongoing Phase 1/2 study of zilovertamab and ibrutinib are encouraging and continue to improve over prior reportingThe ORR of 89% and CR rate of 43% for patients with...